Compare Nuwellis Inc (NUWE) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Verisign, Inc. — how do they compare? Nuwellis Inc trades at $2.94 (market cap $1.09M), while Verisign, Inc. trades at $268.94 (market cap $25.26B). The key difference: Verisign, Inc. is far larger — about 23174.3× Nuwellis Inc's market cap, and Verisign, Inc. pays a 1.17% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| NUWE | VRSN | |
|---|---|---|
Market Cap | $1.09M | $25.26B |
Sector | Technology | Technology |
52-Week High | $527.46 | $310.00 |
52-Week Low | $2.80 | $211.49 |
Enterprise Value | -$722.58K | $26.50B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $3.00, up 5.26% over 24 hours, following a recent 35:1 reverse stock split effective June 26, 2026. The stock shows a bearish technical signal with all moving averages indicating sell. Fundamentally, the company reported a net loss of $17.52M in 2025, with negative profit margins, though revenue grew to $8.27M. Recent news highlights expansion in pediatric care and a $6M public offering closed in June 2026.
Outlook remains challenging due to persistent losses and high cash burn, but strategic initiatives in pediatric cardiorenal care and new patents offer growth potential. Key risks include negative ROE, reliance on financing, and competitive pressures. Analyst consensus is split evenly between Buy and Hold, reflecting cautious optimism amid financial headwinds.
VeriSign (VRSN) trades at $266.15, down 4.15% over the past day, with a mixed technical outlook showing bullish moving averages but overbought oscillators. The company maintains strong fundamentals with 2025 revenue of $1.66 billion, net income of $825.7 million, and a robust net income margin of 49.96%. Recent Q1 2026 earnings beat expectations with EPS of $2.34, while Q2 2026 results are anticipated. Analyst sentiment is predominantly positive with a 57% buy rating and a consensus price target of $325.25, suggesting significant upside potential.
The outlook for VRSN is cautiously optimistic, driven by its monopoly position in .com and .net domain registrations, consistent cash flow generation, and potential tailwinds from AI-driven domain growth. Key risks include contract renewal uncertainties, competitive pressures, and high valuation multiples. Investors should weigh the stock's premium valuation against its stable revenue streams and growth catalysts from digital expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
